Experimental Human Challenge Defines Distinct Pneumococcal Kinetic Profiles and Mucosal Responses between Colonized and Non-Colonized Adults.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

23 citing papers in PubMed, 36 citations in OpenAlex.

1. Muc16 contributes to protection against invasive pneumococcal infection originating from nasal colonization.Microbiology spectrum · 2026
   Article
2. Type I interferon signaling in hematopoietic cells impairs neutrophil antibacterial function in the middle ear during viral co-infection.Cell reports. Medicine · 2026
   Article
3. Bacterial and host factors affecting acquisition ofInfection and immunity · 2026
   Article
4. Streptococcus pneumoniae adaptation to nutrient deprivation and immune modulation drives upper respiratory tract colonization.The ISME journal · 2026
   Article
5. Bacterial and host factors affecting acquisition ofbioRxiv : the preprint server for biology · 2026
   Article
6. Kinetic profile and mucosal capsular polysaccharide IgG responses to serotype 3 pneumococcus in the adult oropharynx following an experimental human challenge.Frontiers in microbiology · 2026
   Article
7. Persistent pneumococcal colonisation in antiretroviral-treated HIV infection is associated with nasal inflammation.Nature communications · 2025
   Article
8. Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development.NPJ vaccines · 2025
   Article
9. Primary human nasal, nasopharyngeal, and bronchial epithelia show distinct immune responses to various pathogens.Pathogens and disease · 2025
   Article
10. Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled study protocol.PloS one · 2025
    Article
11. Serotype 3 Streptococcus pneumoniae Escapes the Immune Responses Induced by PCV13 in Mice With High Susceptibility to Infection.Immunity, inflammation and disease · 2024
    Article
12. Inflammation of the nasal mucosa is associated with susceptibility to experimental pneumococcal challenge in older adults.Mucosal immunology · 2024
    Article
13. Household air pollution and pneumococcal density related to nasopharyngeal inflammation in mothers and children in Ethiopia: A cross-sectional study.PloS one · 2024
    Article
14. Assessing the use of minimally invasive self-sampling at home for long-term monitoring of the microbiota within UK families.Scientific reports · 2023
    Article
15. The quorum sensing com system regulates pneumococcal colonisation and invasive disease in a pseudo-stratified airway tissue model.Microbiological research · 2023
    Article
16. Participant perceptions and experiences of a novel community-based respiratory longitudinal sampling method in Liverpool, UK: A mixed methods feasibility study.PloS one · 2023
    Article
17. Multiplex Hybrid Antigen-Capture LC-MRM Quantification in Sera and Nasal Lining Fluid of AZD7442, a SARS-CoV-2-Targeting Antibody Combination.Analytical chemistry · 2022
    Article
18. Controlled Human Infection Models To Accelerate Vaccine Development.Clinical microbiology reviews · 2022
    Review
19. Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2).BMJ open · 2022
    Article
20. Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2.The Journal of clinical investigation · 2022
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

19 authors at 3 institutions in 4 countries.

Funding

Abstract

Indexed as